Human Viral Oncoproteins and Ubiquitin-Proteasome System

Abstract

Some human cancers worldwide may be related to human tumor viruses. Knowing, controlling, and managing the viruses that cause cancers remain a problem. Also, tumor viruses use ubiquitin-proteasome system (UPS) that can alter host cellular processes through UPS. Human tumor viruses cause persistent infections, due to their ability to infect their host cells without killing them. Tumor viruses such as Epstein-Barr virus, hepatitis C virus, hepatitis B virus, human papillomaviruses, human T cell leukemia virus, Kaposi's sarcoma-associated herpesvirus, and Merkel cell polyomavirus are associated with human malignancies. They interfere with the regulation of cell cycle and control of apoptosis, which are important for cellular functions. These viral oncoproteins bind directly or indirectly to the components of UPS, modifying cellular pathways and suppressor proteins like p53 and pRb. They can also cause progression of malignancy. In this review, we focused on how viral oncoproteins bind to the components of the UPS and how these interactions induce the degradation of cellular proteins for their survival.

Keywords

proteasome / UPS / ubiquitin / oncoprotein / tumor virus

References

[1] Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 2014; 15(03) 266-282

[2] Thomas M, Banks L. Viral oncoproteins and ubiquitination: accessing a cellular toolbox for modifying protein function. FEBS J 2017; 284(19) 3168-3170

[3] Ravid T, Hochstrasser M. Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 2008; 9(09) 679-690

[4] L Aravind EVK. The U box is a modified RING finger - a common domain in ubiquitination. Curr Biol 2000; 10(04) 132-134

[5] Jackson PK, Eldridge AG, Freed E, et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 2000; 10(10) 429-439

[6] Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999; 96(05) 635-644

[7] Ortolan TG, Tongaonkar P, Lambertson D, Chen L, Schauber C, Madura K. The DNA repair protein rad23 is a negative regulator of multi-ubiquitin chain assembly. Nat Cell Biol 2000; 2(09) 601-608

[8] Blanchette P, Branton PE. Manipulation of the ubiquitin-proteasome pathway by small DNA tumor viruses. Virology 2009; 384(02) 317-323

[9] Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 1997; 94(23) 12616-12621

[10] Dantuma NP, Heessen S, Lindsten K, Jellne M, Masucci MG. Inhibition of proteasomal degradation by the Gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc Natl Acad Sci U S A 2000; 97(15) 8381-8385

[11] Holowaty MN, Zeghouf M, Wu H, et al. Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J Biol Chem 2003; 278(32) 29987-29994

[12] Quinn LL, Williams LR, White C, Forrest C, Zuo J, Rowe M. The missing link in Epstein-Barr virus immune evasion: the BDLF3 gene induces ubiquitination and downregulation of major histocompatibility complex class I (MHC-I) and MHC-II. J Virol 2015; 90(01) 356-367

[13] Full F, Hahn AS, Großkopf AK, Ensser A. Gammaherpesviral tegument proteins, PML-nuclear bodies and the ubiquitin-proteasome system. Viruses 2017; 9(10) 308

[14] Allday MJ, Farrell PJ. Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol 1994; 68(06) 3491-3498

[15] Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A 2011; 108(05) 1919-1924

[16] Banerjee S, Lu J, Cai Q, Sun Z, Jha HC, Robertson ES. EBNA3C augments Pim-1 mediated phosphorylation and degradation of p21 to promote B-cell proliferation. PLoS Pathog 2014; 10(08) e1004304

[17] Knight JS, Sharma N, Robertson ES. SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol 2005; 25(05) 1749-1763

[18] Touitou R, O'Nions J, Heaney J, Allday MJ. Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells. J Gen Virol 2005; 86(Pt 5): 1269-1277

[19] Zancai P, Dal Col J, Piccinin S, et al. Retinoic acid stabilizes p27Kip1 in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45Skp2 and Cks1 proteins. Oncogene 2005; 24(15) 2483-2494

[20] Pei Y, Banerjee S, Jha HC, Sun Z, Robertson ES. An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation. PLoS Pathog 2017; 13(07) e1006500

[21] Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387(6630): 296-299

[22] Eliopoulos AG, Caamano JH, Flavell J, et al. Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway. Oncogene 2003; 22(48) 7557-7569

[23] Harada S, Kieff E. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol 1997; 71(09) 6611-6618

[24] Kim MJ, Yoo JY. Inhibition of hepatitis C virus replication by IFN-mediated ISGylation of HCV-NS5A. J Immunol 2010; 185(07) 4311-4318

[25] Hou W, Tian Q, Zheng J, Bonkovsky HL. Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. Gastroenterology 2010; 138(05) 1909-1919

[26] Gao L, Tu H, Shi ST, et al. Interaction with a ubiquitin-like protein enhances the ubiquitination and degradation of hepatitis C virus RNA-dependent RNA polymerase. J Virol 2003; 77(07) 4149-4159

[27] Pavio N, Taylor DR, Lai MM. Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. J Virol 2002; 76(03) 1265-1272

[28] Varaklioti A, Vassilaki N, Georgopoulou U, Mavromara P. Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem 2002; 277(20) 17713-17721

[29] Yuksek K, Chen WL, Chien D, Ou JH. Ubiquitin-independent degradation of hepatitis C virus F protein. J Virol 2009; 83(02) 612-621

[30] Shoji I. Roles of the two distinct proteasome pathways in hepatitis C virus infection. World J Virol 2012; 1(02) 44-50

[31] Suzuki R, Moriishi K, Fukuda K, et al. Proteasomal turnover of hepatitis C virus core protein is regulated by two distinct mechanisms: a ubiquitin-dependent mechanism and a ubiquitin-independent but PA28gamma-dependent mechanism. J Virol 2009; 83(05) 2389-2392

[32] Shirakura M, Murakami K, Ichimura T, et al. E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein. J Virol 2007; 81(03) 1174-1185

[33] Ikeda F, Deribe YL, Skånland SS, et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature 2011; 471(7340): 637-641

[34] Tokunaga F, Nakagawa T, Nakahara M, et al. SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex. Nature 2011; 471(7340): 633-636

[35] Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012; 61(Suppl. 01) i6-i17

[36] Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012; 1: e00049

[37] Qian G, Jin F, Chang L, Yang Y, Peng H, Duan C. NIRF, a novel ubiquitin ligase, interacts with hepatitis B virus core protein and promotes its degradation. Biotechnol Lett 2012; 34(01) 29-36

[38] Wang Z, Ni J, Li J, Shi B, Xu Y, Yuan Z. Inhibition of hepatitis B virus replication by cIAP2 involves accelerating the ubiquitin-proteasome-mediated destruction of polymerase. J Virol 2011; 85(21) 11457-11467

[39] Leupin O, Bontron S, Schaeffer C, Strubin M. Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death. J Virol 2005; 79(07) 4238-4245

[40] Kalra N, Kumar V. The X protein of hepatitis B virus binds to the F box protein Skp2 and inhibits the ubiquitination and proteasomal degradation of c-Myc. FEBS Lett 2006; 580(02) 431-436

[41] Minor MM, Slagle BL. Hepatitis B virus HBx protein interactions with the ubiquitin proteasome system. Viruses 2014; 6(11) 4683-4702

[42] Kong F, You H, Kong D, Zheng K, Tang R. The interaction of hepatitis B virus with the ubiquitin proteasome system in viral replication and associated pathogenesis. Virol J 2019; 16(01) 73

[43] Sharma P, Nag A. CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases. Open Biol 2014; 4(02) 130217

[44] Hodgson AJ, Hyser JM, Keasler VV, Cang Y, Slagle BL. Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication. Virology 2012; 426(01) 73-82

[45] Huang J, Kwong J, Sun EC, Liang TJ. roteasome complex as a potential Üellular target of hepatitis B virus X rotein. J Virol 1996; Aug; 70(08) 5582-5591

[46] King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ. Virus taxonomy: classification and nomenclature of viruses. Ninth Report of the International Committee on Taxonomy of Viruses. Elsevier; Amsterdam: 2012

[47] López-Bueno A, Mavian C, Labella AM, et al. Concurrence of iridovirus, polyomavirus, and a unique member of a new group of fish papillomaviruses in lymphocystis disease-affected gilthead sea bream. J Virol 2016; 90(19) 8768-8779

[48] Pietsch EC, Murphy ME. Low risk HPV-E6 traps p53 in the cytoplasm and induces p53-dependent apoptosis. Cancer Biol Ther 2008; 7(12) 1916-1918

[49] Bernard X, Robinson P, Nominé Y, et al. Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain. PLoS One 2011; 6(10) e25981

[50] de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324(01) 17-27

[51] Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26(04) 612-619

[52] Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9(06) 347-356

[53] Scheffner M, Whitaker NJ. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 2003; 13(01) 59-67

[54] zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2(05) 342-350

[55] Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75(03) 495-505

[56] Grossman SR, Mora R, Laimins LA. Intracellular localization and DNA-binding properties of human papillomavirus type 18 E6 protein expressed with a baculovirus vector. J Virol 1989; 63(01) 366-374

[57] Schwarz SE, Rosa JL, Scheffner M. Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7. J Biol Chem 1998; 273(20) 12148-12154

[58] White EA, Sowa ME, Tan MJ, et al. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci U S A 2012; 109(05) E260-E267

[59] Oh KJ, Kalinina A, Wang J, Nakayama K, Nakayama KI, Bagchi S. The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase. J Virol 2004; 78(10) 5338-5346

[60] Tedesco D, Lukas J, Reed SI. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes Dev 2002; 16(22) 2946-2957

[61] Wang J, Sampath A, Raychaudhuri P, Bagchi S. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene 2001; 20(34) 4740-4749

[62] Berezutskaya E, Bagchi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J Biol Chem 1997; 272(48) 30135-30140

[63] Menon S, Rossi R, Benoy I, Bogers JP, van den Broeck D. Human papilloma virus infection in HIV-infected women in Belgium: implications for prophylactic vaccines within this subpopulation. Eur J Cancer Prev 2018; 27(01) 46-53

[64] Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56(20) 4620-4624

[65] Oh ST, Longworth MS, Laimins LA. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. J Virol 2004; 78(05) 2620-2626

[66] Bhatia S, Afanasiev O, Nghiem P. Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr Oncol Rep 2011; 13(06) 488-497

[67] Chang Y, Moore PS. Merkel cell carcinoma: a virus-induced human cancer. Annu Rev Pathol 2012; 7: 123-144

[68] Kwun HJ, Wendzicki JA, Shuda Y, Moore PS, Chang Y. Merkel cell polyomavirus small T antigen induces genome instability by E3 ubiquitin ligase targeting. Oncogene 2017; 36(49) 6784-6792

[69] Borchert S, Czech-Sioli M, Neumann F, et al. High-affinity Rb binding, p53 inhibition, subcellular localization, and transformation by wild-type or tumor-derived shortened Merkel cell polyomavirus large T antigens. J Virol 2014; 88(06) 3144-3160

[70] Pietropaolo V, Prezioso C, Moens U. Merkel cell polyomavirus and Merkel cell carcinoma. Cancers (Basel) 2020; 12(07) 1774

[71] Dye KN, Welcker M, Clurman BE, Roman A, Galloway DA. Merkel cell polyomavirus tumor antigens expressed in Merkel cell carcinoma function independently of the ubiquitin ligases Fbw7 and β-TrCP. PLoS Pathog 2019; 15(01) e1007543

[72] Wendzicki JA. Comparative analyses of tumorigenic mechanisms of Merkel cell polyomavirus T antigens. University of Pittsburgh; 2019

[73] Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med 2000; 342(14) 1027-1038

[74] Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010; 10(10) 707-719

[75] Stürzl M, Zietz C, Monini P, Ensoli B. Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis. Adv Cancer Res 2001; 81: 125-159

[76] Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266(5192): 1865-1869

[77] Boshoff C, Endo Y, Collins PD, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997; 278(5336): 290-294

[78] Ganem D. KSHV and Kaposi's sarcoma: the end of the beginning?. Cell 1997; 91(02) 157-160

[79] Kaul R, Verma SC, Robertson ES. Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA. Virology 2007; 364(02) 317-329

[80] Sarid R, Wiezorek JS, Moore PS, Chang Y. Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter. J Virol 1999; 73(02) 1438-1446

[81] Borah S, Verma SC, Robertson ES. ORF73 of herpesvirus saimiri, a viral homolog of Kaposi's sarcoma-associated herpesvirus, modulates the two cellular tumor suppressor proteins p53 and pRb. J Virol 2004; 78(19) 10336-10347

[82] Cai Q, Verma SC, Lu J, Robertson ES. Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res 2010; 78: 87-142

[83] Cathomas G. Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) as a tumour virus. Herpes 2003; 10(03) 72-77

[84] Suzuki T, Isobe T, Kitagawa M, Ueda K. Kaposi's sarcoma-associated herpesvirus-encoded LANA positively affects on ubiquitylation of p53. Biochem Biophys Res Commun 2010; 403(02) 194-197

[85] Cai Q, Xiao B, Si H, et al. Kaposi's sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylation. PLoS Pathog 2012; 8(03) e1002566

[86] Gallo RC. History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. Oncogene 2005; 24(39) 5926-5930

[87] Gonçalves DU, Proietti FA, Ribas JG, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev 2010; 23(03) 577-589

[88] Manns A, Blattner WA. The epidemiology of the human T-cell lymphotrophic virus type I and type II: etiologic role in human disease. Transfusion 1991; 31(01) 67-75

[89] Mahieux R, Gessain A. The human HTLV-3 and HTLV-4 retroviruses: new members of the HTLV family. Pathol Biol (Paris) 2009; 57(02) 161-166

[90] Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980; 77(12) 7415-7419

[91] de Castro-Amarante MF, Pise-Masison CA, McKinnon K, et al. Human T cell leukemia virus type 1 infection of the three monocyte subsets contributes to viral burden in humans. J Virol 2015; 90(05) 2195-2207

[92] Franchini G, Mann DL, Popovic M, Zicht RR, Gallo RC, Wong-Staal F. HTLV-I infection of T and B cells of a patient with adult T-cell leukemia-lymphoma (ATLL) and transmission of HTLV-I from B cells to normal T cells. Leuk Res 1985; 9(11) 1305-1314

[93] Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7(04) 270-280

[94] Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG. In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol 1990; 64(11) 5682-5687

[95] Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 2005; 24(39) 6047-6057

[96] Giam CZ, Semmes OJ. HTLV-1 infection and adult T-cell leukemia/lymphoma-a tale of two proteins: Tax and HBZ. Viruses 2016; 8(06) 161

[97] Kajiyama W, Kashiwagi S, Ikematsu H, Hayashi J, Nomura H, Okochi K. Intrafamilial transmission of adult T cell leukemia virus. J Infect Dis 1986; 154(05) 851-857

[98] Kaplan JE, Khabbaz RF, Murphy EL, et al; The Retrovirus Epidemiology Donor Study Group. Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12(02) 193-201

[99] Murphy EL, Figueroa JP, Gibbs WN, et al. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1989; 111(07) 555-560

[100] Ureta-Vidal A, Angelin-Duclos C, Tortevoye P, et al. Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: implication of high antiviral antibody titer and high proviral load in carrier mothers. Int J Cancer 1999; 82(06) 832-836

[101] Marriott SJ, Semmes OJ. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 2005; 24(39) 5986-5995

[102] Pise-Masison CA, Radonovich M, Dohoney K, et al. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood 2009; 113(17) 4016-4026

[103] Chiari E, Lamsoul I, Lodewick J, Chopin C, Bex F, Pique C. Stable ubiquitination of human T-cell leukemia virus type 1 tax is required for proteasome binding. J Virol 2004; 78(21) 11823-11832

[104] Kehn K, Fuente CdeL, Strouss K, et al. The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. Oncogene 2005; 24(04) 525-540

RIGHTS & PERMISSIONS

2024 Global Medical Genetics